[HTML][HTML] [177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer
U Hennrich, M Eder - Pharmaceuticals, 2022 - mdpi.com
In March 2022,[177Lu] Lu-PSMA-617 (PluvictoTM) was approved by the FDA for the
treatment of prostate cancer patients. Until now, the approval has been limited to patients …
treatment of prostate cancer patients. Until now, the approval has been limited to patients …
Radioactive main group and rare earth metals for imaging and therapy
TI Kostelnik, C Orvig - Chemical reviews, 2018 - ACS Publications
Radiometals possess an exceptional breadth of decay properties and have been applied to
medicine with great success for several decades. The majority of current clinical use …
medicine with great success for several decades. The majority of current clinical use …
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Background Progressive metastatic castration-resistant prostate cancer is a highly lethal
disorder and new effective therapeutic agents that improve patient outcomes are urgently …
disorder and new effective therapeutic agents that improve patient outcomes are urgently …
225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer
C Kratochwil, F Bruchertseifer, FL Giesel… - Journal of Nuclear …, 2016 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer.
Recently, we started the first-in-human treatment with an α-radionuclide–labeled PSMA …
Recently, we started the first-in-human treatment with an α-radionuclide–labeled PSMA …
German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients
K Rahbar, H Ahmadzadehfar… - Journal of Nuclear …, 2017 - Soc Nuclear Med
177Lu-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy
(RLT) of patients with metastatic castration-resistant prostate cancer (mCRPC). Initiated by …
(RLT) of patients with metastatic castration-resistant prostate cancer (mCRPC). Initiated by …
[177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Summary Background Lutetium-177 [177 Lu] Lu-PSMA-617 is a radiolabelled small
molecule that delivers β radiation to cells expressing prostate-specific membrane antigen …
molecule that delivers β radiation to cells expressing prostate-specific membrane antigen …
EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)
C Kratochwil, WP Fendler, M Eiber, R Baum… - European journal of …, 2019 - Springer
Prostate-specific membrane antigen (PSMA) is expressed in most prostate cancers and can
be identified by PSMA-ligand imaging, which has already become clinically accepted in …
be identified by PSMA-ligand imaging, which has already become clinically accepted in …
[HTML][HTML] F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients
FL Giesel, B Hadaschik, J Cardinale, J Radtke… - European journal of …, 2017 - Springer
Purpose The prostate-specific membrane antigen (PSMA) targeted positron-emitting-
tomography (PET) tracer 68 Ga-PSMA-11 shows great promise in the detection of prostate …
tomography (PET) tracer 68 Ga-PSMA-11 shows great promise in the detection of prostate …
Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA
B Feuerecker, R Tauber, K Knorr, M Heck, A Beheshti… - European urology, 2021 - Elsevier
Abstract Background Beta-emitting Lu-177-labeled prostate-specific membrane antigen
(PSMA) radioligand therapy (RLT) is a new option for metastatic castration-resistant prostate …
(PSMA) radioligand therapy (RLT) is a new option for metastatic castration-resistant prostate …
[HTML][HTML] EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor-and PSMA-targeting ligands
K Sjögreen Gleisner, N Chouin, PM Gabina… - European journal of …, 2022 - Springer
The purpose of the EANM Dosimetry Committee is to provide recommendations and
guidance to scientists and clinicians on patient-specific dosimetry. Radiopharmaceuticals …
guidance to scientists and clinicians on patient-specific dosimetry. Radiopharmaceuticals …